AR075029A1 - METHOD TO PRODUCE A PROTEIN OR A PHYSIOLOGICALLY ACTIVE PEPTIDE USING AN IMMUNOGLOBULIN FRAGMENT - Google Patents

METHOD TO PRODUCE A PROTEIN OR A PHYSIOLOGICALLY ACTIVE PEPTIDE USING AN IMMUNOGLOBULIN FRAGMENT

Info

Publication number
AR075029A1
AR075029A1 ARP100100113A AR075029A1 AR 075029 A1 AR075029 A1 AR 075029A1 AR P100100113 A ARP100100113 A AR P100100113A AR 075029 A1 AR075029 A1 AR 075029A1
Authority
AR
Argentina
Prior art keywords
protein
physiologically active
produce
immunoglobulin fragment
active peptide
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Byung Sun Lee
Se Chang Kwon
Gwan Sun Lee
Sung Youb Jung
Jin-Sun Kim
Jong-Soo Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR075029A1 publication Critical patent/AR075029A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Método para producir en masa una proteína o un péptido fisiologicamente activo usando una proteína de fusion compuesta de la proteína o del péptido fisiologicamente activo y un fragmento de inmunoglobulina. También se provee dicha proteína de fusion, un ADN que codifica la proteína de fusion, un vector de expresion que comprende el ADN, y un microorganismo transformado con el vector de expresion.Method for mass producing a physiologically active protein or peptide using a fusion protein composed of the physiologically active protein or peptide and an immunoglobulin fragment. Said fusion protein is also provided, a DNA encoding the fusion protein, an expression vector comprising the DNA, and a microorganism transformed with the expression vector.

ARP100100113 2009-01-19 2010-01-19 METHOD TO PRODUCE A PROTEIN OR A PHYSIOLOGICALLY ACTIVE PEPTIDE USING AN IMMUNOGLOBULIN FRAGMENT AR075029A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20090004234 2009-01-19

Publications (1)

Publication Number Publication Date
AR075029A1 true AR075029A1 (en) 2011-03-02

Family

ID=42340231

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100113 AR075029A1 (en) 2009-01-19 2010-01-19 METHOD TO PRODUCE A PROTEIN OR A PHYSIOLOGICALLY ACTIVE PEPTIDE USING AN IMMUNOGLOBULIN FRAGMENT

Country Status (4)

Country Link
KR (1) KR20100084996A (en)
AR (1) AR075029A1 (en)
TW (1) TW201031752A (en)
WO (1) WO2010082804A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1759001T3 (en) 2004-04-21 2011-09-30 Alexion Pharma Inc Bone delivery conjugates and method of using same to target proteins to bone
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (en) 2014-12-05 2019-01-24 Alexion Pharma Inc Treating seizure with recombinant alkaline phosphatase.
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN108350440A (en) 2015-08-17 2018-07-31 阿雷克森制药公司 The manufacture of alkaline phosphate ester
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
KR20190129058A (en) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 How to treat hypophosphatase (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020060202A1 (en) * 2018-09-18 2020-03-26 한국생산기술연구원 Expression cassette for preparing thymulin or argireline, and use thereof
KR102124035B1 (en) * 2018-09-18 2020-06-19 한국생산기술연구원 A expression cassette for preparation of thymulin and use thereof
CN111208243B (en) * 2018-11-21 2022-05-17 中国科学院大连化学物理研究所 Anion exchange chromatographic column-based SUMO peptide fragment enrichment method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
ES2378167T3 (en) * 2003-11-13 2012-04-09 Hanmi Holdings Co., Ltd Protein complex that uses immunoglobulin fragment and the method for its preparation

Also Published As

Publication number Publication date
WO2010082804A2 (en) 2010-07-22
KR20100084996A (en) 2010-07-28
TW201031752A (en) 2010-09-01
WO2010082804A3 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
AR075029A1 (en) METHOD TO PRODUCE A PROTEIN OR A PHYSIOLOGICALLY ACTIVE PEPTIDE USING AN IMMUNOGLOBULIN FRAGMENT
NI201300143A (en) GLUCAGON / GLP-1 RECEPTOR COAGONIST
CL2013001124A1 (en) Isolated antibody or a protein comprising an antigen binding portion of an antibody directed against a cd40 polypeptide; pharmaceutical composition comprising said antibody; nucleic acid encoding the antibody; cloning vector; antibody production process.
DOP2013000178A (en) TREATMENT OF OSTEOARTHRITIS AND PAIN
PE20110593A1 (en) MULTI-SPECIFIC ANTIBODIES
MX2014005108A (en) Polypeptide constructs and uses thereof.
NZ596658A (en) Dig-10 insecticidal cry toxins
CY1116842T1 (en) SPECIFICALLY HUMANIZED ANTIBODIES IN THE PROTEINOLOGICAL FORM OF BETA-AMYLOID Peptide
CR20110679A (en) SUBCUTANEOUS FORMULATION OF ANTI-HER2 ANTIBODY
AR095432A1 (en) PROTEINS OF UNION TO ANTIGEN
CL2008002349A1 (en) Human cd37-binding antibody molecule; DNA molecule that encodes it; expression vector and host cell; method of producing said antibody; pharmaceutical composition comprising it; In vitro method of suppressing cd37-expressing b cells in a population of cells.
PE20220960A1 (en) PROTEINS OF VARIANTS OF AMINO ACID SEQUENCES OF CRY1DA1 ACTIVE FOR LEPIDOPTERA
EA201290964A1 (en) Peptide Conjugates of GLP-1 Receptor Agonists and Their Use
AR076941A1 (en) BACILLUS CEPA FOR A GREATER PROTEIN PRODUCTION
CL2008002444A1 (en) Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
EA201171060A1 (en) MOLECULES OF ANTIBODIES WITH PECULIARITY OF THE HUMAN OH40
PE20141542A1 (en) DUAL FUNCTION PROTEINS TO TREAT METABOLIC DISORDERS
BR112014011404A2 (en) antibody molecules specific for human ox40
EA200900492A1 (en) ANTIBODY MOLECULES THAT ASSOCIATE WITH IL-17A AND IL-17F
AR071232A1 (en) HYBRID PROTEIN USED AS A VACCINE AGAINST SHIGA TOXINS BY E. COLI
EA201300915A1 (en) NEW EUROPEAN PRRSV STRAIN
RU2013134126A (en) METHOD FOR REDUCING THE LEVEL OF THE C-END BODY COLLAGEN TYPE 2
EA201491155A1 (en) NEW MUTANT PRO-NRF AND THEIR APPLICATION TO GET BETA-NRF
PE20201067A1 (en) ANTI-CSF 1R ANTIBODIES
AR080658A1 (en) BACILLUS THURINGIENSIS CRY DIG-5 INSECTICIATED TOXINS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal